Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05573984 · ClinicalTrials.gov registry record
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
A clinical trial of Retinitis Pigmentosa and Eye Diseases, Hereditary, sponsored by PYC Therapeutics.
- Active
- Registry status
- 50
- Enrollment target
- 7
- Study locations
NCT05573984: Active study of Retinitis Pigmentosa and Eye Diseases, Hereditary, sponsored by PYC Therapeutics.
NCT05573984 is a study of Retinitis Pigmentosa and Eye Diseases, Hereditary that is active but no longer recruiting, run by PYC Therapeutics. The registered enrollment target is 50 participants, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (81% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05573984, a study of Retinitis Pigmentosa and Eye Diseases, Hereditary, is active but no longer recruiting, sponsored by PYC Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.
Primary Outcome
BCVA letter score utilizing ETDRS (Early Treatment Diabetic Retinopathy Study) or BRVT (Berkeley Rudimentary Vision Test) for patients not able to see letters
Conditions Studied
Study Locations (7)
California
- University of California San Francisco - San Francisco
Florida
- University of Florida Health - Jacksonville
Michigan
- University of Michigan Kellogg Eye Center - Ann Arbor
Oregon
- Oregon Health and Science University - Casey Eye Institute - Portland
Texas
- Retina Foundation of the Southwest - Dallas
Western Australia
- Lions Eye Institute - Nedlands
Other
- Centre For Eye Research Australia (CERA) - Retinal Gene Therapy Unit - East Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2026-02-28 |
What the registry record for NCT05573984 still lists
NCT05573984 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (81% lower).
The record links to 5 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 0 interventions.
NCT05573984 lists 7 locations in 7 states (California, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT05573984 about?
NCT05573984 is a clinical study titled "Natural History of PRPF31 Mutation-Associated Retinal Dystrophy". The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and fun...
What is the current status of trial NCT05573984?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2022-07-07. Estimated completion is 2026-02-28.
What conditions does trial NCT05573984 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive.
Who is sponsoring clinical trial NCT05573984?
This trial is sponsored by PYC Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05573984 being conducted?
This trial has 7 study locations across California, Florida, Michigan, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05573984's enrollment target sits among peer trials
50 17th of 37 higher than 21 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Retinal Imaging in Patients With Inherited Retinal Degenerations
RECRUITING
-
Cell Collection to Study Eye Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI